Phosphatidylinositol 3-Kinases, antagonists & inhibitors

Name
Phosphatidylinositol 3-Kinases, antagonists & inhibitors
Accession Number
DBCAT001500  (DBCAT001679)
Description

Not Available

Drugs
DrugDrug Description
LY-294002Specific inhibitor of phosphatidylinositol 3-kinase.
XL765For the treatment of various forms of cancer.
TG100-115Investigated for use/treatment in angioedema and myocardial infarction.
PictilisibPictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and Non-Hodgkin's Lymphoma, Solid Cancers, among others.
BuparlisibBuparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
PilaralisibPilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors,...
FimepinostatFimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.
DuvelisibAn inhibitor of phosphatidylinositol 3-kinase delta and gamma used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
PF-04691502PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
AlpelisibAlpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer. This cancer must be hormone receptor (HR)-positive, human epidermal growth factor...
TaselisibTaselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.
ApitolisibApitolisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, and Endometrial Carcinoma, among others.
VoxtalisibVoxtalisib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Breast Cancer, among others.
OmipalisibOmipalisib has been used in trials studying the treatment of CANCER, Solid Tumours, and Idiopathic Pulmonary Fibrosis.
PIK-75PIK-75 is a preferential p110 alpha/gamma PI3K inhibitor.
Drugs & Drug Targets
DrugTargetType
LY-294002Serine/threonine-protein kinase pim-1target
LY-294002Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget
XL765Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
XL765Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget
XL765Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
XL765Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformtarget
XL765Serine/threonine-protein kinase mTORtarget
TG100-115Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
TG100-115Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget
PilaralisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DuvelisibCytochrome P450 3A4enzyme
DuvelisibP-glycoprotein 1transporter
DuvelisibATP-binding cassette sub-family G member 2transporter
DuvelisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget
DuvelisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
AlpelisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
AlpelisibCytochrome P450 3A4enzyme
AlpelisibCytochrome P450 2C9enzyme
AlpelisibCytochrome P450 2C8enzyme
AlpelisibCytochrome P450 2C19enzyme
AlpelisibATP-binding cassette sub-family G member 2transporter
AlpelisibP-glycoprotein 1transporter